Growing Stronger by Delivering on Our Purpose, Passion and Promise February 2021 February 2021 1 Safe Harbor Statement This otherwise successfully integrated, and the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limi ...

Hologic, Inc. (NASDAQ:HOLX) Q1 2021 Earnings Conference Call January 27, 2021 4:30 PM ET Company Representatives Steve MacMillan - Chairman, President, Chief Executive Officer Karleen Oberton, - Chief Financial Officer Mike Watts - Vice President of Investor Relations, Corporate Communications Conference Call Participants Dan Leonard - Wells Fargo Patrick Donnelly - Citi Chris Lin - Cowen Tycho Peterson - J.P. Morgan Raj Denhoy - Jefferies Jack Meehan - Nephron Research Daniel Markowitz - Evercore ISI Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOGIC, INC. (Exact name of registrant as specified in its c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 _________________________________________________ ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2020 was $1.347 billion, representing a 70.9% organic growth year-over-year, while non-GAAP earnings per share (EPS) were $2.07, more than tripling compared to the previous year [9][31] - For the full fiscal year 2020, organic revenue growth was 22% and non-GAAP EPS growth was 64% [15][28] - Gross margin increased to 74.2%, up 1,250 basis points, and operating margin rose to 53.7%, an increase of 2,430 basis points [36][37] Business Line Data and Key Metrics Changes - Diagnostics division revenue more than tripled, with molecular sales increasing by 371%, driven by the shipment of approximately 25 million COVID tests, generating $601 million in revenue [32] - Breast Health division reported global sales of $289.2 million, a decrease of 16.2%, but the interventional business remained flat due to the relaunch of the Brevera biopsy system [33] - Surgical division sales were $100.2 million, down 12.9%, but showed improvement compared to previous quarters [34] Market Data and Key Metrics Changes - Domestic sales increased by 52% to $994.9 million, while international sales roughly doubled to $352.1 million, growing 95% organically, particularly in Europe [35] - The company is on track to generate over $1 billion in total European revenue, with committed COVID revenue expected to exceed $600 million [18][19] Company Strategy and Development Direction - The company aims to produce at least 75 million total molecular diagnostic tests per quarter by the end of 2021, significantly increasing capacity from pre-COVID levels [23][22] - Hologic is focusing on expanding its diagnostics platform and pursuing acquisitions to enhance growth, with a strong emphasis on maintaining cash flow discipline [50][51] - The company is also enhancing its market positioning through contributions to the pandemic response, which is expected to benefit other product lines [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for COVID testing, even post-vaccine, highlighting the importance of asymptomatic testing [52][53] - The company anticipates strong financial results for Q1 2021, with revenue guidance between $1.35 billion and $1.425 billion, reflecting continued growth [40][41] - There is an expectation of gradual recovery in non-COVID related business lines, particularly in Breast Health and Surgical divisions [44][45] Other Important Information - The company repurchased approximately 1.7 million shares for about $100 million in Q4 2020, totaling 13 million shares for $654 million for the full year [28][39] - Hologic's cash flow from operations was $442 million in Q4, contributing to a strong balance sheet with $701 million in cash at the end of the quarter [38][39] Q&A Session Summary Question: Focus on M&A and COVID revenues - Management indicated a focus on broadening the diagnostics platform through acquisitions, while remaining within annual cash flow constraints [50][51] Question: Asymptomatic testing implications - Management believes the asymptomatic approval will drive ongoing demand for testing, even post-vaccine, as governments will likely continue monitoring health [52][53] Question: Sustainability of operating margins - Operating margins are expected to remain strong, with guidance for EPS in Q1 2021 indicating continued robust demand [56][57] Question: Capacity expansion challenges - Management discussed the incremental nature of capacity expansion, with some delays expected in the immediate quarters [66][67] Question: Performance in Breast Health - The Breast Health division is expected to gradually improve, with a focus on service and disposable products contributing positively [70][71]

Hologic, Inc. (NASDAQ:HOLX) Q3 2020 Results Conference Call July 29, 2020 4:30 PM ET Company Participants Mike Watts - VP, IR and Corporate Communications Steve MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi. Chris Lin - Cowen Tycho Peterson - JP Morgan Dan Leonard - Wells Fargo Brian Weinstein - William Blair Jack Meehan - Nephron Research Anthony Petrone - Jefferies Dan Brennan - UBS Ivy Ma - Bank of America Richard Newitter - SVB Leerink ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 27, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HOLOGI ...

Reintroducing a Unique Asset in Women's Health May 2020 May 2020 1 Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resource ...

Hologic, Inc. (NASDAQ:HOLX) Q2 2020 Earnings Conference Call April 29, 2020 4:30 PM ET Company Participants Michael Watts - VP, IR & Corporate Communications Stephen MacMillan - Chairman, CEO & President Karleen Oberton - CFO Conference Call Participants Tycho Peterson - JPMorgan Chase & Co. Patrick Donnelly - Citigroup Brian Weinstein - William Blair & Company Doug Schenkel - Cowen and Company Ivy Ma - Bank of America Merrill Lynch Anthony Petrone - Jefferies David Lewis - Morgan Stanley Daniel Leonard - W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q HOLOGIC, INC. (Exact name of registrant as specified in its charter) __________________________________________________________ or Massachusetts 01752 Delaware 04-2902449 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 250 Campus Drive, Marlborough, (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...